This page shows the latest Betaferon news and features for those working in and with pharma, biotech and healthcare.
However Bayer will lose out after failing to offer a price cut on its Betaferon that is big enough to sway NICE.
But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s
treatment Betaferon/Betaseron (down 11% to 734m).
a year at peak and compensating for slowing sales of older products such as Betaferon/Betaseron (interferon beta-1b) for multiple sclerosis.
The new long-acting formulation will give Biogen Idec a competitive advantage over interferon rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon
Plegridy's dosing gives Biogen Idec a competitive advantage over Avonex rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon beta-1a), and
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...